Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, Ceriello A, Chiodini P, Esposito K
Effect of dulaglutide on kidney function-related outcomes in type 2 diabetes: post hoc analysis from the REWIND Trial
Dominari et al., 2021
La OMS en septiembre aadi los medicamentos GLP-1 como tratamiento para la diabetes a su lista de medicamentos esenciales, pero no los aadi solo para la obesidad
Without doubt, glutathione has earned its status as our bodys strongest antioxidant
Elevated resting heart rate is an independent risk factor for adverse outcomes in heart failure, and beta-blocker therapy to reduce heart rate is a cornerstone of HFrEF management